<DOC>
	<DOCNO>NCT01002664</DOCNO>
	<brief_summary>The hypothesis study examine whether MCS-2 safe effective treatment low urinary tract symptom suggestive benign prostatic hyperplasia .</brief_summary>
	<brief_title>Efficacy Safety MCS-2 Treatment Lower Urinary Tract Symptoms</brief_title>
	<detailed_description>Eligible male subject randomize receive either MCS-2 placebo 12 week . Subjects currently medicine BPH LUTS . During end 12-week treatment period , randomized subject evaluate efficacy safety parameter . All subject advise maintain normal diet , similar consume joining study .</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Lower Urinary Tract Symptoms</mesh_term>
	<criteria>Age ≧ 40 year old . Not treated BPH LUTS . PSA ≦ 4 ng/ml pathologicallyproven prostate cancer . IPSS ≥ 10 No known malignancy AST/ALT ≦ 3X UNL . Creatinine ≦ 3X UNL . Subjects sign inform consent form . Subjects ' LUTS BPHrelated Have treat pelvis irradiation pelvic surgery . Plan undergo invasive procedure within study period . Active infection inflammation . Considered ineligible investigator .</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Benign Prostatic Hyperplasia</keyword>
	<keyword>Multi-carotenoids</keyword>
	<keyword>MCS-2</keyword>
	<keyword>Lower Urinary Tract Symptoms</keyword>
	<keyword>International prostate symptom score</keyword>
</DOC>